Zetia vs Repatha: Real-World Evidence Comparison

What These Two Drugs Actually Do

Ezetimibe blocks NPC1L1 receptors in the gut wall, cutting dietary and biliary cholesterol absorption by roughly 50%. Evolocumab is a fully human monoclonal antibody that binds PCSK9, preventing it from degrading LDL receptors on hepatocytes. These are different mechanisms at different points in the cholesterol pathway, which is why their LDL-lowering magnitudes differ so sharply.

Mechanism Differences Matter for Combination Therapy

Because ezetimibe acts in the intestine and evolocumab acts on hepatic LDL-receptor recycling, combining either drug with a statin produces additive effects through distinct pathways. Statin therapy upregulates PCSK9 expression by 30 to 40% [1], which partially explains why PCSK9 inhibitors produce larger absolute LDL reductions on a statin background than off one. Ezetimibe does not carry this interaction.

FDA Approval Scope

The FDA approved ezetimibe (Zetia) in 2002 for primary hypercholesterolemia, sitosterolemia, and homozygous familial hypercholesterolemia [2]. Evolocumab (Repatha) received FDA approval in 2015 for heterozygous and homozygous familial hypercholesterolemia and, separately in 2017, for cardiovascular risk reduction in established atherosclerotic disease [3]. The cardiovascular outcomes indication for evolocumab is broader and explicitly tied to FOURIER data.

LDL-C Lowering: Numbers From Trials and Registries

The LDL-C difference between the two drugs is not subtle.

IMPROVE-IT Data for Ezetimibe

IMPROVE-IT enrolled 18,144 patients post-acute coronary syndrome and randomized them to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo over a median 6-year follow-up. The combination arm achieved a median LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the placebo arm, a 15.8 mg/dL absolute difference [4]. That translates to roughly 24% additional LDL-C reduction on top of statin therapy. The trial was powered to detect a difference in the composite of cardiovascular death, nonfatal MI, unstable angina requiring rehospitalization, coronary revascularization, or nonfatal stroke.

FOURIER Data for Evolocumab

FOURIER enrolled 27,564 patients with established atherosclerotic cardiovascular disease already on optimized statin therapy. Evolocumab 140 mg every 2 weeks or 420 mg monthly reduced LDL-C from a median baseline of 92 mg/dL to 30 mg/dL, a 59% reduction [5]. At 48 weeks, 42% of evolocumab-treated patients achieved LDL-C <25 mg/dL. No comparable proportion was seen in any ezetimibe trial.

Real-World Registry Confirmation

A 2021 analysis from the Swedish SWEDEHEART registry (N=22,742 post-MI patients) found that ezetimibe added to statin reduced LDL-C by a mean 0.51 mmol/L (approximately 19.7 mg/dL) in routine clinical practice, consistent with IMPROVE-IT [6]. Separately, the HEYMANS real-world evolocumab registry published in the European Heart Journal (2022, N=1,204) showed evolocumab reduced LDL-C by 56.3% at 12 months outside the trial setting [7]. Real-world attrition due to adherence attenuates both effects modestly, but the relative magnitude holds.

Cardiovascular Outcomes: Comparing the Trial Endpoints

LDL-C numbers are surrogate endpoints. What patients and clinicians care about is whether these drugs prevent heart attacks and strokes.

IMPROVE-IT Outcomes

In IMPROVE-IT, the primary composite endpoint (cardiovascular death, major coronary event, or nonfatal stroke) occurred in 32.7% of the ezetimibe group versus 34.7% of the placebo group over 7 years. That is a 6.4% relative risk reduction and a 2.0 percentage-point absolute risk reduction [4]. The number needed to treat over 7 years was 50. Post-hoc analyses showed the benefit was concentrated in higher-risk subgroups: diabetic patients had a 14% relative risk reduction compared with 0% in non-diabetic patients [8].

FOURIER Outcomes

FOURIER's primary endpoint was a composite of cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization. At a median 2.2 years, evolocumab reduced this endpoint from 11.3% to 9.8%, a 15% relative risk reduction and 1.5 percentage-point absolute reduction [5]. The key secondary endpoint (cardiovascular death, MI, or stroke) showed a 20% relative risk reduction. The absolute risk reduction continued to grow with longer follow-up in the open-label extension FOURIER-OLE, where patients followed for up to 8.4 years showed sustained and deepening cardiovascular benefit [9].

Indirect Comparison Caveat

These trials enrolled different populations at different baseline risks over different durations. IMPROVE-IT patients were post-ACS with a higher absolute event rate at baseline. FOURIER patients had stable established disease. Direct statistical comparison of relative risk reductions between trials is not valid without individual patient data meta-analysis, but the ACC/AHA 2022 guidelines explicitly place evolocumab one tier higher than ezetimibe for very-high-risk patients precisely because of the larger LDL-C effect size [10].

Safety Profiles: What Real-World Data Add

Both drugs are generally well tolerated, but their adverse effect profiles differ in ways that matter for patient selection.

Ezetimibe Safety

Ezetimibe's most commonly reported adverse effects in IMPROVE-IT were myalgia (5.9% vs 5.7% placebo) and hepatic enzyme elevations (3.2% vs 3.3% placebo), neither of which was statistically different from placebo [4]. Rare cases of myopathy have been reported when ezetimibe is combined with a statin, but the rate is not higher than statin monotherapy [11]. A 2020 JAMA Internal Medicine analysis of real-world pharmacovigilance data from the FDA Adverse Event Reporting System found no new safety signals for ezetimibe beyond those identified in pre-market trials [12].

Evolocumab Safety

In FOURIER, injection-site reactions occurred in 2.1% of evolocumab patients versus 1.6% of placebo patients [5]. Neurocognitive adverse events received regulatory attention after early case reports; a dedicated sub-study (EBBINGHAUS, N=1,974) found no difference in cognitive function between evolocumab and placebo at 19 months using the Cambridge Neuropsychological Test Automated Battery [13]. The FDA label for evolocumab includes no cognitive warning. Long-term safety out to 5 years in FOURIER-OLE showed no new signals, including no increase in new-onset diabetes, which is a concern with high-dose statin therapy [9].

Injection vs. Oral Route

Ezetimibe is one tablet daily. Evolocumab requires a subcutaneous injection every 2 weeks (140 mg autoinjector) or once monthly (420 mg via three 140 mg injections or a single-use prefilled cartridge). Real-world adherence studies show 12-month persistence is 60 to 65% for evolocumab versus 70 to 75% for ezetimibe [14], a gap attributable in part to the injection burden and in part to insurance prior-authorization requirements.

Pharmacoeconomics and Access

Cost is not a secondary concern. It shapes whether patients fill their prescriptions.

List Price and Generic Availability

Generic ezetimibe has been available in the United States since 2017. A 30-day supply costs $10 to 30 at most major pharmacies. Evolocumab's list price remains approximately $5,800 per year ($484/month) after the manufacturer reduced it 60% in 2018 [15]. Even at the reduced price, the cost-effectiveness of evolocumab depends heavily on patient baseline risk.

Cost-Effectiveness Thresholds

A 2019 analysis published in the Journal of the American College of Cardiology modeled evolocumab's incremental cost-effectiveness ratio at $28,000, $45,000 per quality-adjusted life year (QALY) when prescribed to patients with established atherosclerosis and LDL-C ≥70 mg/dL despite maximally tolerated statin plus ezetimibe therapy, which falls below the conventional $100,000/QALY threshold [16]. For lower-risk patients, the same model estimated a cost-effectiveness ratio exceeding $300,000/QALY, making evolocumab economically unjustifiable as a first add-on agent.

Insurance and Prior Authorization

The ACC/AHA 2022 cholesterol guidelines recommend a stepwise approach: maximally tolerated statin first, then ezetimibe, then a PCSK9 inhibitor for very-high-risk patients with LDL-C ≥70 mg/dL [10]. Most commercial insurers and Medicare Part D plans require documented statin plus ezetimibe failure before approving evolocumab. The prior authorization process adds 2 to 6 weeks of delay in typical practice [17].

Who Should Switch From Zetia to Repatha?

This question comes up in clinic regularly, and the evidence supports a clear framework.

Patients Likely to Benefit From Switching

Patients who should be considered for evolocumab include those with established atherosclerotic cardiovascular disease (prior MI, stroke, or peripheral arterial disease), LDL-C remaining ≥70 mg/dL on maximally tolerated statin plus ezetimibe 10 mg daily, and no contraindications to injection therapy. The ACC/AHA "very high risk" designation applies to patients with two or more major ASCVD events or one major event plus multiple high-risk conditions such as diabetes, hypertension, chronic kidney disease, or current smoking [10].

In FOURIER subgroup analyses, patients with LDL-C ≥92 mg/dL at baseline (the median) had larger absolute risk reductions than those below the median, confirming that residual LDL elevation amplifies the evolocumab benefit [5].

Patients for Whom Zetia Remains Appropriate

Patients with primary prevention indications (no established ASCVD), moderately elevated LDL-C, or LDL-C already near target on a statin typically do not meet criteria for evolocumab. For these patients, ezetimibe added to a statin remains the evidence-based second-line choice. IMPROVE-IT showed a statistically significant reduction in the primary endpoint in this population, confirming ezetimibe's clinical utility independent of its lower magnitude of LDL lowering [4].

Patients who cannot self-inject or who lack reliable insurance coverage also represent a practical contraindication to evolocumab. A 2022 survey of 612 cardiologists published in JAMA Cardiology found that 67% cited insurance denial as the most common barrier to PCSK9 inhibitor prescribing, not clinical ineligibility [18].

Combination Use (Zetia Plus Repatha)

Adding ezetimibe to evolocumab produces a further 20 to 25% LDL-C reduction beyond evolocumab alone in patients with familial hypercholesterolemia. The GAUSS-3 trial (N=511) documented that patients with statin intolerance on ezetimibe alone achieved an LDL-C of 183 mg/dL; evolocumab added to ezetimibe brought median LDL-C to 103 mg/dL, a 47% reduction [19]. For homozygous familial hypercholesterolemia patients, combination therapy including ezetimibe, a PCSK9 inhibitor, and lomitapide or inclisiran may be necessary to reach guideline targets.

Guideline Recommendations

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol provides the most authoritative framework for choosing between these agents [10].

ACC/AHA 2022 Hierarchy

The guideline specifies: "For patients with clinical ASCVD who are at very high risk and have LDL-C ≥70 mg/dL or non-HDL-C ≥100 mg/dL while on maximally tolerated statin therapy and ezetimibe, a PCSK9 inhibitor is recommended (Class I, Level A)." This places evolocumab (and alirocumab) as a third-line agent after ezetimibe, not an alternative to it.

For primary prevention in patients with LDL-C ≥190 mg/dL despite maximally tolerated statin therapy, the 2022 guideline rates ezetimibe as a Class IIa recommendation before PCSK9 inhibitors [10].

ESC/EAS 2019 European Alignment

The 2019 ESC/EAS guidelines on dyslipidaemia reach a similar conclusion, recommending PCSK9 inhibitors for very-high-risk patients who fail to achieve LDL-C targets on maximally tolerated statin plus ezetimibe. The European target for very-high-risk patients is LDL-C <55 mg/dL, which most patients cannot reach on ezetimibe alone without a PCSK9 inhibitor [20].

Adherence and Real-World Effectiveness

A drug's clinical trial efficacy means little if patients do not take it.

Ezetimibe Adherence Data

A 2020 analysis of the OptumInsight claims database (N=87,341 statin-plus-ezetimibe initiators) found 12-month medication possession ratio ≥80% in 68.4% of patients, declining to 59.1% at 24 months [21]. Adherence did not differ significantly by sex, age, or race in this cohort.

Evolocumab Adherence Data

The PATH registry (N=2,895 evolocumab-treated patients in real-world European centers) reported 12-month persistence of 62% with a mean LDL-C reduction of 54% among persistent users, compared with 36% reduction across the full intention-to-treat cohort due to discontinuations [22]. Injection-site reactions and insurance gaps were the two leading reasons for stopping.

Implications for Prescribing

These adherence patterns mean that at a population level, ezetimibe's per-patient LDL-C reduction may modestly exceed what evolocumab achieves when discontinuation is factored in. That does not reverse the per-patient efficacy advantage of evolocumab in those who remain adherent, but it does underscore the need for structured follow-up at 3 and 6 months after starting either agent.

Biomarker Monitoring on Each Drug

Monitoring requirements differ and influence clinical workflow.

What to Check on Ezetimibe

The ACC/AHA 2022 guideline recommends a fasting lipid panel 4 to 12 weeks after starting or changing a lipid-lowering regimen, then every 3 to 12 months thereafter [10]. No routine liver function monitoring is required for ezetimibe monotherapy given the absence of hepatotoxicity signal in IMPROVE-IT. A baseline ALT and creatine kinase are reasonable before initiating any new lipid-lowering agent.

What to Check on Evolocumab

The same 4 to 12 week lipid panel applies to evolocumab. Patients on evolocumab who achieve LDL-C <20 mg/dL do not require dose reduction; FOURIER-OLE data show no harm from sustained very low LDL-C, with cardiovascular event rates continuing to decline at LDL-C values as low as 10 to 15 mg/dL [9]. Some clinicians add a lipoprotein(a) measurement at baseline, as FOURIER sub-analyses showed evolocumab reduced Lp(a) by approximately 27% and that Lp(a) reduction independently predicted event reduction [23].